NY-CELONIS
14.5.2024 08:01:35 CEST | Business Wire | Press release
Celonis, the global leader in Process Mining, announced today that it has been named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the second time since the category's inception last year. Celonis was evaluated and placed in the Leaders’ Quadrant, being positioned highest on the Ability to Execute axis and advancing to the furthest spot on the Completeness of Vision axis once again.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513067064/en/
Celonis is a Leader in the 2024 Gartner Magic Quadrant for Process Mining Platforms, placed highest on the Ability to Execute and highest on Completeness of Vision. (Graphic: Business Wire)
“The pace of change keeps accelerating - new technologies keep emerging, customer expectations keep rising, and the need for greater efficiency keeps increasing. To succeed, organizations need solutions that help them address all these demands, and most importantly create meaningful value,” said Alex Rinke, co-CEO and co-founder of Celonis. “Celonis gives companies a common language for how their business runs and provides the context to enable technologies like AI and automation to become effective. For us, being named a Leader for the second consecutive year in the Gartner Magic Quadrant for Process Mining Platforms reinforces our commitment to make processes work for people, companies and the planet. We are proud to receive this recognition and will continue to build the future of process intelligence together with our customers, partners and fellow Celonauts who have embraced our vision and keep pushing process mining to realize its full potential.”
“Process mining has become an essential enterprise solution for adapting to an uncertain world and driving transformation at speed and scale,” said Daniel de Rooij, SVP Digital Transformation and CIO Hygiene at Reckitt, a global consumer products company with well-known brands such as Finish dishwasher tablets, Lysol disinfectant, and Nurofen painkillers. “With advancements like object-centric process mining and the Process Intelligence Graph, Celonis’ platform provides us with the unique process intelligence that we need to optimize IT operations, deliver value to the business faster, and drive disruptive innovation with emerging technologies like generative AI.”
Celonis enables customers to identify and capture hidden value, empower their people with actionable insights, and help them more effectively leverage technologies like AI and automation to optimize their processes. At the core of the Celonis Platform is the Process Intelligence Graph (PI Graph), an extensible digital twin of the business based on a standardized, object-centric data model. This twin is system-agnostic and without bias. The PI Graph adds business context to this process digital twin with out-of-the-box KPI definitions and improvement opportunities, such as how delivery blocks impact on-time delivery rate. Sitting at the heart of the Celonis platform, the PI Graph allows us to create capabilities that embed AI in ready-to-use solutions. For example, the Process Copilot chatbot turns natural language requests into process insights, and the AI-powered Duplicate Checker App helps keep customers from paying invoices twice. Using our Machine Learning (ML) Workbench customers and partners can create their own AI solutions in Celonis or feed data into their existing AI tools using our Intelligence API.
The platform also provides advanced process modeling functionality. In 2023, Celonis acquired Symbio, a provider of AI-driven Business Process Management (BPM) software. The integration of Symbio’s capabilities into the Celonis platform enables customers to not only mine their processes and identify value opportunities, but also design their ideal process using a modern, AI-assisted process modeling solution. Customers can also ensure their processes stay on the straight and narrow with the Process Adherence Manager and track the business impact of their process improvement work with the Transformation Hub.
Notes to editors
The 2024 Gartner Magic Quadrant on Process Mining Platforms is available here.
Find more information on Process Mining and the Celonis Process Intelligence Platform here.
Gartner, Magic Quadrant for Process Mining Platforms, Marc Kerremans, David Sudgen, Nick Duffy, 29 April 2024
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Celonis
Since 2011, Celonis has helped thousands of the world’s largest and most esteemed companies yield immediate cash impact, radically improve customer experience, and reduce carbon emissions. Its Process Intelligence platform uses industry-leading process mining technology and AI to present companies with a living digital twin of their end-to-end processes. For the first time, everyone in an organization has a common language for how the business runs, visibility into where value is hiding, and the ability to capture it. Celonis is headquartered in Munich, Germany and New York City, USA with more than 20 offices worldwide.
© 2024 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513067064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
